These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1592 related articles for article (PubMed ID: 23891763)

  • 1. Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF rats.
    Schwasinger-Schmidt T; Robbins DC; Williams SJ; Novikova L; Stehno-Bittel L
    Pharmacol Res; 2013 Oct; 76():58-66. PubMed ID: 23891763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Automated recognition and quantification of pancreatic islets in Zucker diabetic fatty rats treated with exendin-4.
    Kakimoto T; Kimata H; Iwasaki S; Fukunari A; Utsumi H
    J Endocrinol; 2013 Jan; 216(1):13-20. PubMed ID: 23092878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Taspoglutide, a novel human once-weekly GLP-1 analogue, protects pancreatic β-cells in vitro and preserves islet structure and function in the Zucker diabetic fatty rat in vivo.
    Uhles S; Wang H; Bénardeau A; Prummer M; Brecheisen M; Sewing S; Tobalina L; Bosco D; Wollheim CB; Migliorini C; Sebokova E
    Diabetes Obes Metab; 2011 Apr; 13(4):326-36. PubMed ID: 21205124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurturin and a GLP-1 Analogue Act Synergistically to Alleviate Diabetes in Zucker Diabetic Fatty Rats.
    Trevaskis JL; Sacramento CB; Jouihan H; Ali S; Le Lay J; Oldham S; Bhagroo N; Boland BB; Cann J; Chang Y; O'Day T; Howard V; Reers C; Winzell MS; Smith DM; Feigh M; Barkholt P; Schreiter K; Austen M; Andag U; Thompson S; Jermutus L; Coghlan MP; Grimsby J; Dohrmann C; Rhodes CJ; Rondinone CM; Sharma A
    Diabetes; 2017 Jul; 66(7):2007-2018. PubMed ID: 28408435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Voluntary running exercise prevents β-cell failure in susceptible islets of the Zucker diabetic fatty rat.
    Delghingaro-Augusto V; Décary S; Peyot ML; Latour MG; Lamontagne J; Paradis-Isler N; Lacharité-Lemieux M; Akakpo H; Birot O; Nolan CJ; Prentki M; Bergeron R
    Am J Physiol Endocrinol Metab; 2012 Jan; 302(2):E254-64. PubMed ID: 22045312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. beta-cell failure in diabetes and preservation by clinical treatment.
    Wajchenberg BL
    Endocr Rev; 2007 Apr; 28(2):187-218. PubMed ID: 17353295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
    Montanya E; Sesti G
    Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Influences of exendin-4 on the secretion function of islet beta cells from rats in the early stage of severe scald].
    Zhao DX; Ma L; Shen ZA; Li DW; Shang YR; Yin K; Cheng WF; Wang X; Liu ZX
    Zhonghua Shao Shang Za Zhi; 2016 Dec; 32(12):752-758. PubMed ID: 28043300
    [No Abstract]   [Full Text] [Related]  

  • 9. Synergistic effect of the human GLP-1 analogue liraglutide and a dual PPARalpha/gamma agonist on glycaemic control in Zucker diabetic fatty rats.
    Brand CL; Galsgaard ED; Tornehave D; Rømer J; Gotfredsen CF; Wassermann K; Knudsen LB; Vølund A; Sturis J
    Diabetes Obes Metab; 2009 Aug; 11(8):795-803. PubMed ID: 19519868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of the insulin sensitizer, pioglitazone, and the long-acting GLP-1 human analog, liraglutide, exerts potent synergistic glucose-lowering efficacy in severely diabetic ZDF rats.
    Larsen PJ; Wulff EM; Gotfredsen CF; Brand CL; Sturis J; Vrang N; Knudsen LB; Lykkegaard K
    Diabetes Obes Metab; 2008 Apr; 10(4):301-11. PubMed ID: 18333889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combination of colesevelam with sitagliptin enhances glycemic control in diabetic ZDF rat model.
    Shang Q; Liu MK; Saumoy M; Holst JJ; Salen G; Xu G
    Am J Physiol Gastrointest Liver Physiol; 2012 Apr; 302(8):G815-23. PubMed ID: 22281473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
    Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR
    J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive factors of efficacy of combination therapy with basal insulin and liraglutide in type 2 diabetes when switched from longstanding basal-bolus insulin: Association between the responses of β- and α-cells to GLP-1 stimulation and the glycaemic control at 6 months after switching therapy.
    Horie I; Haraguchi A; Sako A; Akeshima J; Niri T; Shigeno R; Ito A; Nozaki A; Natsuda S; Akazawa S; Mori Y; Ando T; Kawakami A; Abiru N
    Diabetes Res Clin Pract; 2018 Oct; 144():161-170. PubMed ID: 30194951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dapagliflozin promotes beta cell regeneration by inducing pancreatic endocrine cell phenotype conversion in type 2 diabetic mice.
    Wei R; Cui X; Feng J; Gu L; Lang S; Wei T; Yang J; Liu J; Le Y; Wang H; Yang K; Hong T
    Metabolism; 2020 Oct; 111():154324. PubMed ID: 32712220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liraglutide and sitagliptin counter beta- to alpha-cell transdifferentiation in diabetes.
    Tanday N; Flatt PR; Irwin N; Moffett RC
    J Endocrinol; 2020 Apr; 245(1):53-64. PubMed ID: 31977315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next-generation GLP-1 therapy: an introduction to liraglutide.
    Repas T
    Postgrad Med; 2011 Sep; 123(5):239-47. PubMed ID: 21904107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positive effects of GLP-1 receptor activation with liraglutide on pancreatic islet morphology and metabolic control in C57BL/KsJ db/db mice with degenerative diabetes.
    Moffett RC; Patterson S; Irwin N; Flatt PR
    Diabetes Metab Res Rev; 2015 Mar; 31(3):248-55. PubMed ID: 25256010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liraglutide, a human glucagon-like peptide-1 analogue, stimulates AKT-dependent survival signalling and inhibits pancreatic β-cell apoptosis.
    Kapodistria K; Tsilibary EP; Kotsopoulou E; Moustardas P; Kitsiou P
    J Cell Mol Med; 2018 Jun; 22(6):2970-2980. PubMed ID: 29524296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liraglutide prevents fast weight gain and β-cell dysfunction in male catch-up growth rats.
    Zheng J; Chen T; Zhu Y; Li HQ; Deng XL; Wang QH; Zhang JY; Chen LL
    Exp Biol Med (Maywood); 2015 Sep; 240(9):1165-76. PubMed ID: 25710926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of β-Cell Identity Occurs in Type 2 Diabetes and Is Associated With Islet Amyloid Deposits.
    Spijker HS; Song H; Ellenbroek JH; Roefs MM; Engelse MA; Bos E; Koster AJ; Rabelink TJ; Hansen BC; Clark A; Carlotti F; de Koning EJ
    Diabetes; 2015 Aug; 64(8):2928-38. PubMed ID: 25918235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 80.